$22.99
▼ $-0.42
(-1.79%)
Vol 595K
12
Quality Score
ok
Deep Check
1/5
fail
Rev ✗
NI ✓
>IPO ✗
Mkt Cap
$1.5B
P/E
11.7
ROE
16.6%
Margin
32.8%
D/E
25.48
Beta
0.44
52W
$17–$23
Wall Street Consensus
11 analysts · Apr 20264
Strong Buy
5
Buy
1
Hold
1
Sell
0
Strong Sell
81.8%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $0.56 | $1.94 | +$1.38 |
| Sep 2025 | $0.49 | $1.08 | +$0.59 |
| Jun 2025 | $0.51 | $0.77 | +$0.26 |
| Mar 2025 | $0.30 | $-0.74 | $-1.04 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $91.8M | $88.6M | $100.3M | $107.8M | $114.6M |
| Net Income | — | $20.3M | -$46.6M | $63.7M | $89.9M | $164.2M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | 5.7% | 5.7% | 5.7% | 5.7% | 16.6% | 16.6% |
| P/E (TTM) | 32.63 | 33.13 | 29.64 | 29.68 | 12.22 | 11.74 |
| Net Margin | 63.5% | 10.4% | 10.4% | 10.4% | 32.8% | 32.8% |
| Gross Margin | 82.9% | 86.6% | 86.6% | 86.6% | 81.5% | 81.5% |
| D/E Ratio | 62.80 | 62.80 | 62.80 | 62.80 | 25.48 | 25.48 |
| Current Ratio | 2.64 | 2.64 | 2.64 | 2.64 | 14.12 | 14.12 |
Key Ratios
ROA (TTM)
9.6%
P/S (TTM)
3.85
P/B
1.6
EPS (TTM)
$1.26
CF/Share
$1.03
Rev Growth 3Y
-2.9%
52W High
$22.76
52W Low
$16.52
$16.52
52-Week Range
$22.76
Financial Health
Free Cash Flow
$54.5M
Net Debt
-$281.9M
Cash
$550.9M
Total Debt
$269.0M
As of Dec 31, 2025
How does INVA compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
INVA valuation vs Pharmaceuticals peers
P/E ratio
11.7
▼
48%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
3.9
▼
22%
below
peers
(5.0)
vs Peers
vs Industry
Pricier
P/B ratio
1.6
▼
26%
below
peers
(2.1)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
INVA profitability vs Pharmaceuticals peers
ROE
16.6%
▲
131%
above
peers
(-54.3%)
vs Peers
vs Industry
Top tier
Net margin
32.8%
▲
169%
above
peers
(-47.4%)
vs Peers
vs Industry
Below avg
Gross margin
81.5%
▲
19%
above
peers
(68.3%)
vs Peers
vs Industry
Weak
ROA
9.6%
▲
126%
above
peers
(-37.4%)
vs Peers
vs Industry
Top tier
INVA financial health vs Pharmaceuticals peers
D/E ratio
25.5
▲
1555%
above
peers
(1.5)
vs Peers
vs Industry
High debt
Current ratio
14.1
▲
320%
above
peers
(3.4)
vs Peers
vs Industry
Strong liquidity
Beta
0.4
▼
53%
below
peers
(0.9)
vs Peers
vs Industry
More volatile
INVA fundamentals radar
INVA
Peer median
Industry
INVA profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
INVA vs peers: key metrics
Top Holders
Top 5: 40.47%Blackrock Inc.
14.41%
$243.3M
Vanguard Group Inc
10.69%
$180.4M
Dimensional Fund Advisors LP
5.89%
$99.4M
Renaissance Technologies, L…
5.68%
$95.9M
Sarissa Capital Management,…
3.80%
$64.2M
As of Dec 31, 2025
Dividends
$1.00
/ year
Sep 08, 2015
$0.2500
Jun 10, 2015
$0.2500
Mar 10, 2015
$0.2500
Nov 21, 2014
$0.2500
Aug 26, 2014
$0.2500